Squarepoint’s INmune Bio INMB Stock Holding History

Squarepoint’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$18.1K	Buy	16,030 +2,732	+21%	+$3.89K	﹤0.01%	4177
2025 Q4	$20.7K	Sell	13,298 -1,264	-9%	-$2.25K	﹤0.01%	4167
2025 Q3	$30.1K	Buy	+14,562	New	+$33.3K	﹤0.01%	4267
2024 Q4	–	Sell	-33,701	Closed	-$182K	–	5252
2024 Q3	$182K	Buy	+33,701	New	+$240K	﹤0.01%	3719
2024 Q2	–	Sell	-13,441	Closed	-$158K	–	4350
2024 Q1	$158K	Buy	+13,441	New	+$162K	﹤0.01%	3689
2023 Q4	–	Sell	-10,308	Closed	-$70.5K	–	4239
2023 Q3	$70.5K	Buy	+10,308	New	+$85.5K	﹤0.01%	3603
2023 Q2	–	Sell	-13,045	Closed	-$84.3K	–	3772
2023 Q1	$84.3K	Buy	+13,045	New	+$105K	﹤0.01%	3001

Other funds holding INMB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Squarepoint's INMB Position: Q1 2026 in Review

Squarepoint increased its INmune Bio (INMB) stake by 21% in Q1 2026, buying an estimated $3.89K and bringing the position to 16,030 shares worth $18.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4177.

Squarepoint first reported a position in INMB in Q1 2023 and has held it in 7 quarters since. The position peaked at $182K in Q3 2024. 82 funds tracked by Wall St. Rank hold INMB as of Q1 2026.

Squarepoint held 16,030 shares of INmune Bio worth $18.1K as of Q1 2026.
Squarepoint bought 2,732 INmune Bio shares in Q1 2026, an estimated $3.89K.
INmune Bio made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #4177 holding.
Squarepoint first reported a position in INmune Bio in Q1 2023 and has held it in 7 quarters since.
Squarepoint's INmune Bio position peaked at $182K in Q3 2024.
82 funds tracked by Wall St. Rank held INmune Bio as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.